DNA is in our blood

Natera^™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. Our mission is to change the management of disease worldwide by using information gained from a simple blood draw to proactively inform treatment.

Corporate Story Women's Health, Organ Health, Oncology

Next-generation cell-free DNA testing

Through our next-generation, cell-free DNA (cfDNA) technology platform, we’ve pioneered noninvasive blood-based testing in the fields of women’s health, oncology, and organ health.

Focused on experience and support

At Natera, we’re building an entirely new way to manage genetic testing: in the cloud. We’ve made it possible to virtually order tests, schedule mobile blood draws, access test results, and consult with genetic counselors — all with the click of a button. Our global footprint spans 90 countries worldwide, putting DNA testing within reach.

Our mission is personal

Applying clinical expertise, leading-edge technology and operational excellence to change the management of disease worldwide

Natera was born from a deeply personal desire to change the way disease was managed.

“In 2004, my sister gave birth to a son with Down Syndrome. He passed away six days after birth. It was a devastating experience for our entire family. I founded Natera because I believe all families deserve access to technologies that offer early detection of genetic disease.”

Matthew Rabinowitz

Founder of Natera

Since its founding, Natera has pushed the boundaries of testing management with a proven track record of scientific excellence and innovation.


2004		Natera, Inc. is founded by Matthew Rabinowitz, Ph.D. and Jonathan Sheena, M. Eng
2009		Spectrum preimplantation genetic test launches
2010		Anora miscarriage test (POC) launches
2012		Horizon advanced carrier screening test launches
2013		Panorama next-generation NIPT launches
2015		Natera, Inc. holds Initial Public Offering (IPO)
Aug 2016		Natera and USCF collaborate on a study evaluating the use of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients
2017		Vistara single-gene NIPT launches
2017		Signatera molecular residual disease (MRD) test launches (Research Use Only)
Apr 2017		Study published in Nature shows early relapse detection in lung cancer using Natera’s circulating tumor DNA (ctDNA) technology
Aug 2018		Natera and Fox Chase Cancer Center collaborate on kidney cancer study using the Signatera RUO test
Aug 2018		Signatera RUO Test shown to detect molecular residual disease up to 2 years prior to clinical relapse and to predict treatment response in breast cancer
Jan 2019		Steve Chapman appointed CEO
2019		Signatera CLIA test launches
May 2019		FDA grants breakthrough device designation to Natera’s Signatera test
Aug 2019		Panorama NIPT achieves 2 million test milestone
2019		Prospera dd-cfDNA transplant assessment test launches
2020		Empower hereditary cancer test launches
Jun 2020		Natera expands lab footprint with a facility in Austin, Texas
2020		Renasight kidney gene panel launches
Aug 2020		Publication in Nature Cancer shows Signatera’s ability to evaluate tumor response to immunotherapy